Jeffrey W Corbett1. 1. Corbett Drug Discovery Partners LLC, 96 South Beechwood Road, Niantic, CT 06357, USA. corbettconsulting@gmail.com
Abstract
BACKGROUND: Acetyl-CoA carboxylase (ACC) is a biologic target that is receiving increased attention for the treatment of obesity and type 2 diabetes mellitus. Inhibition of this enzyme, either in transgenic mice or pharmacologically, has been shown to have beneficial effects on lab animals. METHOD: This review of the ACC inhibitor patent literature covers the period from mid-2007 to December 2008, during which time a total of 18 patents were published. CONCLUSION: These published patent applications include ACC inhibitors that inhibit the enzyme through modulation of the carboxyltransferase-domain, inhibitors that bind to the biotin carboxylase-domain and novel chemotypes whose mode of action was not disclosed. Furthermore, published patents claim the discovery of ACC2 isoform selective and ACC1/2 non-selective inhibitors.
BACKGROUND:Acetyl-CoA carboxylase (ACC) is a biologic target that is receiving increased attention for the treatment of obesity and type 2 diabetes mellitus. Inhibition of this enzyme, either in transgenic mice or pharmacologically, has been shown to have beneficial effects on lab animals. METHOD: This review of the ACC inhibitor patent literature covers the period from mid-2007 to December 2008, during which time a total of 18 patents were published. CONCLUSION: These published patent applications include ACC inhibitors that inhibit the enzyme through modulation of the carboxyltransferase-domain, inhibitors that bind to the biotin carboxylase-domain and novel chemotypes whose mode of action was not disclosed. Furthermore, published patents claim the discovery of ACC2 isoform selective and ACC1/2 non-selective inhibitors.
Authors: Kyle L Hoehn; Nigel Turner; Michael M Swarbrick; Donna Wilks; Elaine Preston; Yuwei Phua; Himani Joshi; Stuart M Furler; Mark Larance; Bronwyn D Hegarty; Simon J Leslie; Russell Pickford; Andrew J Hoy; Edward W Kraegen; David E James; Gregory J Cooney Journal: Cell Metab Date: 2010-01 Impact factor: 27.287
Authors: Jenny D Y Chow; Robert T Lawrence; Marin E Healy; John E Dominy; Jason A Liao; David S Breen; Frances L Byrne; Brandon M Kenwood; Carolin Lackner; Saeko Okutsu; Valeria R Mas; Stephen H Caldwell; Jose L Tomsig; Gregory J Cooney; Pere B Puigserver; Nigel Turner; David E James; Judit Villén; Kyle L Hoehn Journal: Mol Metab Date: 2014-03-12 Impact factor: 7.422